Interferon-induced depression in hepatitis C: An update

Current Psychiatry Reports

Volumn 9, Issue 3, 2007, Pages 255-261

  Keefe, Brian ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; BETA INTERFERON; CITALOPRAM; ERYTHROPOIETIN; FLUOXETINE; GAMMA INTERFERON; INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PEGINTERFERON; PLACEBO; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANEMIA; ANTIVIRAL ACTIVITY; APPETITE DISORDER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; INCIDENCE; MAJOR DEPRESSION; MELANOMA; MONOTHERAPY; MULTIPLE SCLEROSIS; OFF LABEL DRUG USE; PREVALENCE; PROPHYLAXIS; PSYCHOLOGIC TEST; PSYCHOSIS; REMISSION; REVIEW; RISK FACTOR; SIDE EFFECT; SUICIDAL IDEATION; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; METABOLIC CLEARANCE RATE; PREMEDICATION; REFERRAL AND CONSULTATION;

EID: 34250186449     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-007-0028-4     Document Type: Review

References (42)

1. Szabo E, Lotz G, Paska C, et al.: Viral hepatitis: new data on hepatitis C infection. Pathol Oncol Res 2003, 9:215-221.
2. Wong JB, McQuillan GM, McHutchison IG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000, 90:1562-1569.
3. O'Dwyer AM, Conroy R: Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005, 27:431-438.
4. Constant A, Castera L, Dantzer R, et al.: Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005, 66:1050-1057.
5. Exton MS, Baase J, Pithan V, et al.: Neuropsychological performance and mood states following acute interferon-beta-1b administration in healthy males. Neuropsychobiology 2002, 45:199-204.
6. Golden J, O'Dwyer AM, Conroy RM: Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005, 27:431-438.
7. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
8. Raison CL, Borisov AS, Broadwell SD, et al.: Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005, 66:41-48.
9. Fried MW: Side effects of therapy with hepatitis C and their management. Hepatology 2002, 36(5 Suppl 1):S237-S244.
10. Kraus MR, Schaefer A, Faller H, et al.: Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003, 64:708-714.
11. Horsmans Y: Chronic hepatitis C, depression and interferon. J Hepatol 2005, 42:788-789.
12. Asnis GM, De La Garza R: Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology and treatment approaches. J Clin Gastroenterol 2006, 40:322-335.
13. Hauser P, Khosla J, Aurora H, et al.: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002, 7:942-947.
14. Cotler SJ, Wartelle CF, Larson AM, et al.: Pretreatment symptoms and dosing regiment predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 2000, 7:211-217.
15. Capuron L, Ravaud A, Dantzer R: Timing and specificity of cognitive changes induced by interleukin-2 and interferon alpha treatments in cancer patients. Psychosom Med 2001, 63:376-386.
16. Otsubo T, Miyaoka H, Kamijima K, et al.: Depression during interferon therapy in chronic hepatitis C patients [in Japanese]. Seishin Shinkeigaku Zasshi 1997, 99:101-127.
17. Scalori A, Apale P, Panizzuti F, et al.: Depression during interferon therapy for chronic viral hepatitis: early identification of patients by means of a computerized test. Eur J Gastroenterol Hepatol 2000, 12:505-509.
18. Bonaccorso S, Marino V, Biondi M, et al.: Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002, 72:237-241.
19. Beratis S, Katrivanou A, Georgiou S, et al.: Major depression and the risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment. J Psychosom Res 2005, 58:15-18.
20. Sulkowski MS, Wasserman R, Brooks L, et al.: Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004, 11:243-250.
21. Pockros PJ, Shiffman ML, Schiff ER, et al.: Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004, 40:1450-1458.
22. Dalgard O, Bjoro K, Hellum K, et al.: Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 2002, 251:400-406.
23. Loftis JM, Wall JM, Linardatos E, et al.: A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C. J Endocrinol Invest 2004, 27:RC16-RC20.
24. Asnis GM, De La Garza R, 2nd: Interferon-induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:808-818.
25. Bonaccorso S, Marino V, Puzella A, et al.: Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha induced changes in the serotonergic system. J Clin Psychopharmacol 2002, 22:86-90.
26. Capuraon L, Neurauter G, Musselman DL, et al.: Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 2003, 54:906-914.
27. Schramm T, Lawford B, Macdonald G, Cooksley W: Sertraline treatment of interferon-alpha-induced depressive disorder. Med J Aust 2000, 173:359-361.
28. Kraus MR, Schafer A, Faller H. et al.: Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002, 16:1091-1099.
29. Hauser P, Soler R, Reed S, et al.: Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000, 41:439-441.
30. Musselman DL, Lawson DH, Gumnick JF, et al.: Paroxetine for the prevention of depression induced by high-dose interferon-alpha. N Engl J Med 2001, 344:961-966.
31. Kraus MR, Axhafer A, Al-Taie O, Scheurlen M: Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005, 12:96-100.
32. Schaefer M, Schwaiger M, Garkisch AS, et al.: Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005, 42:880-887.
33. Morasco BJ, Rifai MA, Loftis JM, et al.: A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007 [Epub ahead of print].
34. Loftis JM, Socherman RE, Howell CD, et al.: Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004, 365:87-91.
35. Gleason OC, Yates WR, Philipsen MA, et al.: Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 2004, 45:29-33.
36. Skop B, Brown T: Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996, 37:12-16.
37. Oyesanmi O, Kunkel EF, Monti DA, Field HL: Hematological side effects of psychotropics. Psychosomatics 1999, 40:414-421.
38. de Jong JC, van den Berg PB, Tobi H, de Jong-van den Berg LT. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol 2003, 55:591-595.
39. Edin BR, Seal KH, Lorvick J, et al.: Is it justifiable to withhold treatment for hepatitis C from illicit drug users? N Engl J Med 2001, 345:211-215.
40. National Institutes of Health: National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002, 36(5 Suppl 1):S3-S20.
41. Wichers MC, Koek GH, Robaeys G, et al.: Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psycbol Med 2005, 35:433-441.
42. Fried MW, Hadziyannis SJ: Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis 2004, 24(Suppl 2):47-54.